Weekly Cisplatin New Standard in Postop Head and Neck Cancer Weekly Cisplatin New Standard in Postop Head and Neck Cancer

In a randomized trial, weekly cisplatin plus radiotherapy has been shown to be not only less toxic than dosing once every three weeks but also achieves better outcomes.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news